Drug firm Cadila Healthcare Ltd. on Monday said it has received establishment inspection report from the U.S. health regulator after inspection of its Ahmedabad facility.
The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration signifying the successful closure of the audit, Cadila Healthcare said in a filing to the BSE.
The facility completed the U.S. FDA audit from Dec. 16-20, 2019 with zero 483 observations, it added.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
